Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.25 Consensus PT from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given an average rating of “Hold” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.20.

RXRX has been the subject of several analyst reports. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Morgan Stanley cut their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $5.76 on Thursday. The firm has a market cap of $2.32 billion, a P/E ratio of -3.76 and a beta of 1.00. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm’s 50 day moving average price is $6.83 and its two-hundred day moving average price is $6.84.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the business earned ($0.42) earnings per share. Recursion Pharmaceuticals’s revenue was down 57.8% compared to the same quarter last year. On average, analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the stock. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC increased its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after purchasing an additional 2,387 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.